Advertisement
Canada markets closed
  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     
  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     
  • DOW

    38,225.66
    +322.37 (+0.85%)
     
  • CAD/USD

    0.7318
    +0.0004 (+0.06%)
     
  • CRUDE OIL

    79.14
    +0.19 (+0.24%)
     
  • Bitcoin CAD

    80,463.30
    +1,281.91 (+1.62%)
     
  • CMC Crypto 200

    1,273.29
    +2.55 (+0.20%)
     
  • GOLD FUTURES

    2,311.10
    +1.50 (+0.06%)
     
  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     
  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     
  • NASDAQ futures

    17,749.00
    +99.25 (+0.56%)
     
  • VOLATILITY

    14.68
    -0.71 (-4.61%)
     
  • FTSE

    8,172.15
    +50.91 (+0.63%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6817
    0.0000 (0.00%)
     

CVS names new pharmacy services, consumer product chiefs

FILE PHOTO: Illustration shows CVS Health logo

(Reuters) -CVS Health Corp said on Monday that David Joyner would return to head the U.S. diversified healthcare company's pharmacy services and tapped former Cigna Corp executive Amy Bricker as its chief product officer for consumer business.

Joyner will become the chief of the pharmacy services segment, which also includes the company's pharmacy benefits management business Caremark, effective Jan. 30. He will succeed Alan Lotvin, who plans to retire in April, CVS said.

Bricker will start in the newly created role in February after serving as president of Express Scripts, rival Cigna Corp's pharmacy benefits unit.

The appointments follow some setbacks CVS faced in recent months in its businesses. Its largest health insurance plan for Medicare recipients received a lower performance rating from the U.S. Centers for Medicare and Medicaid Services in October. The lower rating could affect payments from the government for 2024, the company said.

ADVERTISEMENT

In the same month, Centene Corp replaced Caremark with Express Scripts to manage the insurer's annual pharmacy spend of around $40 billion.

The loss of the account, along with the ratings decline, will likely reduce 2024 revenue by $2 billion, CVS said in November.

(Reporting by Raghav Mahobe and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)